

**POLICIES AND PRACTICES FOR STORAGE OF RECORDS:**

Pre-existing paper and microfiche records were digitized. Input records are maintained digitally on electronic storage media in accordance with the safeguards below.

**POLICIES AND PRACTICES FOR RETRIEVAL OF RECORDS:**

Records can be retrieved by name, SSN, employee IDs, organizational code, home address, or a combination of the information listed in the categories of records.

**POLICIES AND PRACTICES FOR RETENTION AND DISPOSAL OF RECORDS:**

Records in the system are maintained in accordance with the following NARA's records retention and schedules: General Records Schedule (GRS) 2.3, Employee Relations Records, Item 10, *Employee relations programs' administrative records*, DAA-GRS-2018-0002-0001, Temporary. Destroy when 3 years old, but longer retention is authorized if required for business use; Item 40, *Telework/alternate worksite program*, DAA GRS-2018-0002-0004, Temporary. Destroy when 3 years old, but longer retention is authorized if required for business use. GRS 2.4, *Employee Compensation and Benefits Records*, Item 10, Records used to calculate payroll, arrange paycheck deposit, and change previously issued paychecks, DAA-2018-0002-0001: Temporary. Destroy when 3 years old, but longer retention is authorized if required for business use. Item 30, Time and attendance records, DAAGRS-2019-0004-0002, Temporary, destroy when 3 years old, but longer retention is authorized if required for business use. Item 40, Agency payroll record for each pay period, DAA-GRS-2016-00015-0004, Destroy when 56 years old. GRS 4.2, *Information Access, and Protection Records*, Item 130, Personally identifiable information extracts, DAA-GRS-2013-0007-0012, Temporary. Destroy when 90 days old or no longer needed pursuant to supervisory authorization, whichever is appropriate.

**ADMINISTRATIVE, TECHNICAL, AND PHYSICAL SAFEGUARDS:**

*Administrative Procedures:* Access to the records is limited to person(s) responsible for servicing the records in performance of their official duties, who are properly screened, trained on policies and procedures, and cleared for need to-know. Personnel who access the system and its data must take security awareness training and sign a Rules of Behavior initially (prior to access) and, at least, annually thereafter. Technical: Regular monitoring of users and the

system are implemented to ensure only authorized personnel have access to information in the system. Strict controls are in place to minimize the compromise of stored or accessed in the system. Physical: The system and the data are housed in secure data center.

**RECORD ACCESS PROCEDURES:**

Individuals seeking access to records about themselves contained in this system should address inquiries to the System Manager at the address identified in "System Manager and Address" above. Request must be in writing, include SORN ID and name of this system of records notice, information on the Operating Administration-Department, specific date range and specific type of records seeking. Request must be signed by the requester, must be notarized as required by 28 U.S.C. 1746 in the following format: If executed without the United States: "I declare (or certify, verify, or state) under penalty of perjury under the laws of the United States of America that the foregoing is true and correct. Executed on (date). (Signature)". If executed within the United States, its territories, possessions, or commonwealths: "I declare (or certify, verify, or state) under penalty of perjury that the foregoing is true and correct. Executed on (date). (Signature)".

**CONTESTING RECORD PROCEDURES:**

See "Records Access Procedures" above.

**NOTIFICATION PROCEDURES:**

See "Records Access Procedures" above.

**EXEMPTIONS PROMULGATED FOR THE SYSTEM:**

None.

**HISTORY:**

A full notice of this system of records, DOT/ALL 11, Integrated Personnel Payroll System, was published in the **Federal Register** on November 7, 2008 (73 FR 66285), April 11, 2000 (65 FR 19845).

Issued in Washington, DC.

**Karyn Gorman,**

*Chief Privacy Officer.*

[FR Doc. 2024-26743 Filed 11-15-24; 8:45 am]

**BILLING CODE 4910-9X-P**

**DEPARTMENT OF VETERANS AFFAIRS**

[OMB Control No. 2900-0890]

**Agency Information Collection Activity Under OMB Review: Industry Standard Forms for Completing an Appraisal Required by VA**

**AGENCY:** Veterans Benefits Administration, Department of Veterans Affairs.

**ACTION:** Notice.

**SUMMARY:** In compliance with the Paperwork Reduction Act (PRA) of 1995, this notice announces that the Veterans Benefits Administration, Department of Veterans Affairs, will submit the collection of information abstracted below to the Office of Management and Budget (OMB) for review and comment. The PRA submission describes the nature of the information collection and its expected cost and burden and it includes the actual data collection instrument.

**DATES:** Comments and recommendations for the proposed information collection should be sent by December 18, 2024.

**ADDRESSES:** To submit comments and recommendations for the proposed information collection, please type the following link into your browser: [www.reginfo.gov/public/do/PRAMain](http://www.reginfo.gov/public/do/PRAMain), select "Currently under Review—Open for Public Comments", then search the list for the information collection by Title or "OMB Control No. 2900-0890."

**SUPPLEMENTARY INFORMATION:**

*Title:* Industry Standard Forms for Completing an Appraisal Required by VA FNMA Forms 1004, 1004C, 1004D, 1004 (Desktop), 1025, 1073, 1075 and 2055

*OMB Control Number:* 2900-0890.

*Type of Review:* Extension without change of a currently approved collection.

*Abstract:* This information collection package seeks approval of VA's requirement that appraisers utilize certain industry-standard forms in completing an appraisal. 38 U.S.C. 3731 authorizes the VA Secretary to establish a panel of appraisers, prescribe qualifications for such appraisers, and determine reasonable value of a property, construction, repairs or alterations based on an appraisal report provided by a panel appraiser for the purpose of guaranteeing a loan.

VA is requesting approval to authorize collection of these forms because accurate and thorough appraisal reporting is critical to the accuracy of underwriting for the mortgage process.

Additionally, VA is looking to expand the list of authorized forms for use due to ongoing needs related to the pandemic. This collection of information provides a more thorough and complete appraisal of prospective VA-guaranteed properties ensuring that mortgages are acceptable for VA guarantee and thereby protect the interest of VA, taxpayers, and the Veterans Housing Benefit Program Fund. Policies and procedures for governing the VA appraisal program are set forth in Chapter 36, Title 38 of the CFR.

An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number.

The **Federal Register** Notice with a 60-day comment period soliciting comments on this collection of information was published at 89 FR 73508, September 10, 2024.

**Affected Public:** Individuals or Households.

**Estimated Annual Burden:** 10,833.

**Estimated Average Burden per Respondent:** 1 minute.

**Frequency of Response:** One time.

**Estimated Number of Respondents:** 650,000.

(Authority: 44 U.S.C. 3501 *et seq.*)

#### Maribel Aponte,

VA PRA Clearance Officer, Office of Enterprise and Integration, Data Governance Analytics, Department of Veterans Affairs.

[FR Doc. 2024-26803 Filed 11-15-24; 8:45 am]

**BILLING CODE 8320-01-P**

## DEPARTMENT OF VETERANS AFFAIRS

### Findings of Research Misconduct

**AGENCY:** Department of Veterans Affairs.

**ACTION:** Notice.

**SUMMARY:** The Department of Veterans Affairs (VA), gives notice, pursuant to Veterans Health Administration (VHA) Directive 1058.02 “Research Misconduct” section 8.l, that the Department has made findings of research misconduct against Alan Lichtenstein, M.D. (“Respondent”), a former staff physician at the VA Greater Los Angeles Healthcare System, Los Angeles, CA. The Respondent did not appeal the findings or corrective actions against him.

**FOR FURTHER INFORMATION CONTACT:** Shara Kabak, Research Misconduct Officer, Office of Research Oversight (10RO), 810 Vermont Avenue NW, Washington, DC 20420, (202) 632-7620 (this is not a toll-free number).

**SUPPLEMENTARY INFORMATION:** VA has made final findings of research misconduct against Alan Lichtenstein, M.D. (“Respondent”), a former staff physician at the VA Greater Los Angeles Healthcare System in Los Angeles, CA.

Based on the recommended findings of a joint investigation conducted by VA Greater Los Angeles Healthcare System and University of California, Los Angeles School of Medicine, the Department found that the Respondent engaged in research misconduct by recklessly falsifying data included in at least ten of the following thirteen published papers:

- DEPTOR is linked to a TORC1-p21 survival proliferation pathway in multiple myeloma. *Genes & Cancer*. 2014 Nov;5(11-12):407-19. doi: 10.18632/genesandcancer.44 (hereafter, “*Genes Cancer 2014*”).

- Cytotoxic properties of a DEPTOR-mTOR inhibitor in multiple myeloma cells. *Cancer Research*. 2016 Oct 1;76(19):5822-5831. doi: 10.1158/0008-5472.CAN-16-1019 (hereafter, “*Cancer Res. 2016*”).

- Interleukin-6 activates phosphoinositol-3 kinase in multiple myeloma tumor cells by signaling through RAS-dependent and, separately, through p85-dependent pathways. *Oncogene*. 2004 Apr 22;23(19):3368-75. doi: 10.1038/sj.onc.1207459 (hereafter, “*Oncogene 2004*”).

- MNK1-induced eIF-4E phosphorylation in myeloma cells: a pathway mediating IL-6-induced expansion and expression of genes involved in metabolic and proteotoxic responses. *PLoS One*. 2014 Apr 8;9(4):e94011. doi: 10.1371/journal.pone.0094011 (hereafter, “*PLoS One 2014*”). Retraction in: *PLoS One*. 2023 Sep 8;18(9):e0291491. doi: 10.1371/journal.pone.0291491.

- Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. *Molecular Cancer Therapeutics*. 2005 Oct;4(10):1533-40. doi: 10.1158/1535-7163.MCT-05-0068 (hereafter, “*Mol Cancer Ther. 2005*”).

- Inhibition of SAPK2/p38 enhances sensitivity to mTORC1 inhibition by blocking IRES-mediated translation initiation in glioblastoma. *Molecular Cancer Therapeutics*. 2011 10:2244-2256 Dec;10(12):2244-56. doi: 10.1158/1535-7163.MCT-11-0478 (hereafter, “*Mol Cancer Ther. 2011*”).

- Specific blockade of Rictor-mTOR association inhibits mTORC2 activity and is cytotoxic in glioblastoma. *PLoS One*. 2017; Apr 28;12(4):e0176599. doi:

10.1371/journal.pone.0176599 (hereafter, “*PLoS One 2017*”). Correction in: *PLoS One*. 2019 Feb 6;14(2):e0212160. doi: 10.1371/journal.pone.0212160. Retraction in: *PLoS One*. 2023 Sep 8;18(9):e0291490. doi: 10.1371/journal.pone.0291490.

- MNK kinases facilitate c-myc IRES activity in rapamycin-treated multiple myeloma. *Oncogene*. 2013 Jan 10;32(2):190-7. doi: 10.1038/onc.2012.43 (hereafter, “*Oncogene 2013*”). Expression of Concern in: *Oncogene*. 2023 Oct;42(41):3088. doi: 10.1038/s41388-023-02818-z.

- The PP242 mammalian target of rapamycin (mTOR) inhibitor activates extracellular signal-regulated kinase (ERK) in multiple myeloma cells via a target of rapamycin complex 1 (TORC1)/eukaryotic translation initiation factor 4E (eIF-4E)/RAF pathway and activation is a mechanism of resistance. *Journal of Biological Chemistry*. 2012 Jun 22;287(26):21796-805. doi: 10.1074/jbc.M111.304626 (hereafter, “*J Biol Chem. 2012*”).

- Therapeutic potential of targeting IRES-dependent c-myc translation in multiple myeloma cells during ER stress. *Oncogene*. 2016 Feb 25;35(8):1015-24. doi: 10.1038/onc.2015.156 (hereafter, “*Oncogene 2016*”). Retraction in: *Oncogene*. 2023 Sep;42(40):3016. doi: 10.1038/s41388-023-02820-5.

- SGK kinase activity in multiple myeloma cells protects against ER stress apoptosis via a SEK-dependent mechanism. *Molecular Cancer Research*. 2016 Apr;14(4):397-407. doi: 10.1158/1541-7786.MCR-15-0422 (hereafter, “*Mol Cancer Res. 2016*”).

- A novel therapeutic induces DEPTOR degradation in multiple myeloma cells with resulting tumor cytotoxicity. *Molecular Cancer Therapeutics*. 2019 Oct;18(10):1822-1831. doi: 10.1158/1535-7163.MCT-19-0115 (hereafter, “*Mol Cancer Ther. 2019*”).

- Downstream effectors of oncogenic ras in multiple myeloma cells. *Blood*. 2003 Apr 15;101(8):3126-35. doi: 10.1182/blood-2002-08-2640 (hereafter, “*Blood 2003*”).

Specifically, the Department found that the Respondent recklessly committed research misconduct by reusing the same Western blot or kinase assay image to falsely represent the results related to the following pairs of experiments such that at least one of the sets of images in each of the pairs listed below is inaccurate:

- p-4E-BP1-T37/46, p-4E-BP1-S65 and Tubulin expression in Figure 3B of *Genes Cancer 2014* and Figure 1F of *Cancer Res. 2016*.